RVL Pharmaceuticals Reports Q1 2023 Net Loss of $11.6 Million
Company's Q1 Revenue Stands at $8.8 Million
RVL Pharmaceuticals PLC,(RVLP) a leading player in the pharm aceutical industry, has released its unaudited condensed consolidated financial statements for the first quarter of 2023. The company's financial report showcases a net loss of $11.6 million for the quarter, accompanied by total revenues of $8.8 million.
Current Assets and Liabilities
The company's unaudited condensed consolidated balance sheet reveals a snapshot of its financial position as of March 31, 2023. RVL Pharmaceuticals' current assets have been recorded at $38.4 million, comprising cash and cash equivalents, accounts receivable, inventories, and prepaid expenses. In contrast, current liabilities amount to $16.4 million, encompassing trade accounts payable, accrued liabilities, and current portions of debt and lease liabilities.
